Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.

McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS; LOFT Investigators.

Lancet Diabetes Endocrinol. 2019 Dec;7(12):899-911. doi: 10.1016/S2213-8587(19)30346-8. Epub 2019 Oct 31.

PMID:
31676222
2.

Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy.

Toth PP, Bays HE, Brown WV, Catapano AL, Davidson MH, Farnier M, Tomassini JE, Jensen E, Polis AB, Tershakovec AM.

J Clin Lipidol. 2019 Nov - Dec;13(6):997-1007.e8. doi: 10.1016/j.jacl.2019.09.001. Epub 2019 Sep 11.

PMID:
31629703
3.

Rodent ketamine depression-related research: Finding patterns in a literature of variability.

Polis AJ, Fitzgerald PJ, Hale PJ, Watson BO.

Behav Brain Res. 2019 Dec 30;376:112153. doi: 10.1016/j.bbr.2019.112153. Epub 2019 Aug 13. Review.

4.

Increasing Diversity in Clinical Trials: Overcoming Critical Barriers.

Clark LT, Watkins L, Piña IL, Elmer M, Akinboboye O, Gorham M, Jamerson B, McCullough C, Pierre C, Polis AB, Puckrein G, Regnante JM.

Curr Probl Cardiol. 2019 May;44(5):148-172. doi: 10.1016/j.cpcardiol.2018.11.002. Epub 2018 Nov 9. Review.

PMID:
30545650
5.

Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia.

Toth PP, Catapano AL, Farnier M, Foody J, Tomassini JE, Jensen E, Polis AB, Hanson ME, Musliner TA, Tershakovec AM.

Am J Cardiol. 2016 Dec 15;118(12):1812-1820. doi: 10.1016/j.amjcard.2016.08.071. Epub 2016 Sep 13.

6.

Time-related trends in variability of cIMT changes in statin trials.

Davidson MH, Tomassini JE, Jensen E, Neff D, Polis AB, Tershakovec AM.

Data Brief. 2015 Dec 30;6:530-41. doi: 10.1016/j.dib.2015.12.029. eCollection 2016 Mar.

7.

Changing characteristics of statin-related cIMT trials from 1988 to 2006.

Davidson MH, Tomassini JE, Jensen E, Neff D, Polis AB, Tershakovec AM.

Atherosclerosis. 2016 Mar;246:121-9. doi: 10.1016/j.atherosclerosis.2015.11.023. Epub 2015 Nov 25.

PMID:
26773471
8.

Measurement and comparison of individual external doses of high-school students living in Japan, France, Poland and Belarus-the 'D-shuttle' project.

Adachi N, Adamovitch V, Adjovi Y, Aida K, Akamatsu H, Akiyama S, Akli A, Ando A, Andrault T, Antonietti H, Anzai S, Arkoun G, Avenoso C, Ayrault D, Banasiewicz M, Banaśkiewicz M, Bernardini L, Bernard E, Berthet E, Blanchard M, Boreyko D, Boros K, Charron S, Cornette P, Czerkas K, Dameron M, Date I, De Pontbriand M, Demangeau F, Dobaczewski Ł, Dobrzyński L, Ducouret A, Dziedzic M, Ecalle A, Edon V, Endo K, Endo T, Endo Y, Etryk D, Fabiszewska M, Fang S, Fauchier D, Felici F, Fujiwara Y, Gardais C, Gaul W, Gurin L, Hakoda R, Hamamatsu I, Handa K, Haneda H, Hara T, Hashimoto M, Hashimoto T, Hashimoto K, Hata D, Hattori M, Hayano R, Hayashi R, Higasi H, Hiruta M, Honda A, Horikawa Y, Horiuchi H, Hozumi Y, Ide M, Ihara S, Ikoma T, Inohara Y, Itazu M, Ito A, Janvrin J, Jout I, Kanda H, Kanemori G, Kanno M, Kanomata N, Kato T, Kato S, Katsu J, Kawasaki Y, Kikuchi K, Kilian P, Kimura N, Kiya M, Klepuszewski M, Kluchnikov E, Kodama Y, Kokubun R, Konishi F, Konno A, Kontsevoy V, Koori A, Koutaka A, Kowol A, Koyama Y, Kozioł M, Kozue M, Kravtchenko O, Kruczała W, Kudła M, Kudo H, Kumagai R, Kurogome K, Kurosu A, Kuse M, Lacombe A, Lefaillet E, Magara M, Malinowska J, Malinowski M, Maroselli V, Masui Y, Matsukawa K, Matsuya K, Matusik B, Maulny M, Mazur P, Miyake C, Miyamoto Y, Miyata K, Miyata K, Miyazaki M, Molȩda M, Morioka T, Morita E, Muto K, Nadamoto H, Nadzikiewicz M, Nagashima K, Nakade M, Nakayama C, Nakazawa H, Nihei Y, Nikul R, Niwa S, Niwa O, Nogi M, Nomura K, Ogata D, Ohguchi H, Ohno J, Okabe M, Okada M, Okada Y, Omi N, Onodera H, Onodera K, Ooki S, Oonishi K, Oonuma H, Ooshima H, Oouchi H, Orsucci M, Paoli M, Penaud M, Perdrisot C, Petit M, Piskowski A, Płocharski A, Polis A, Polti L, Potsepnia T, Przybylski D, Pytel M, Quillet W, Remy A, Robert C, Sadowski M, Saito M, Sakuma D, Sano K, Sasaki Y, Sato N, Schneider T, Schneider C, Schwartzman K, Selivanov E, Sezaki M, Shiroishi K, Shustava I, Śniecińska A, Stalchenko E, Staroń A, Stromboni M, Studzińska W, Sugisaki H, Sukegawa T, Sumida M, Suzuki Y, Suzuki K, Suzuki R, Suzuki H, Suzuki K, Świderski W, Szudejko M, Szymaszek M, Tada J, Taguchi H, Takahashi K, Tanaka D, Tanaka G, Tanaka S, Tanino K, Tazbir K, Tcesnokova N, Tgawa N, Toda N, Tsuchiya H, Tsukamoto H, Tsushima T, Tsutsumi K, Umemura H, Uno M, Usui A, Utsumi H, Vaucelle M, Wada Y, Watanabe K, Watanabe S, Watase K, Witkowski M, Yamaki T, Yamamoto J, Yamamoto T, Yamashita M, Yanai M, Yasuda K, Yoshida Y, Yoshida A, Yoshimura K, Żmijewska M, Zuclarelli E.

J Radiol Prot. 2016 Mar;36(1):49-66. doi: 10.1088/0952-4746/36/1/49. Epub 2015 Nov 27.

PMID:
26613195
9.

Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.

Descamps O, Tomassini JE, Lin J, Polis AB, Shah A, Brudi P, Hanson ME, Tershakovec AM.

Atherosclerosis. 2015 Jun;240(2):482-9. doi: 10.1016/j.atherosclerosis.2015.03.004. Epub 2015 Mar 9.

PMID:
25913444
10.

Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.

Ambegaonkar BM, Tipping D, Polis AB, Tomassini JE, Tershakovec AM.

Atherosclerosis. 2014 Dec;237(2):829-37. doi: 10.1016/j.atherosclerosis.2014.10.105. Epub 2014 Nov 4.

PMID:
25463129
11.

Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model.

Bays HE, Chen E, Tomassini JE, McPeters G, Polis AB, Triscari J.

Fundam Clin Pharmacol. 2015 Apr;29(2):209-18. doi: 10.1111/fcp.12096. Epub 2015 Feb 27.

PMID:
25431239
12.

Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.

Farnier M, Guyton JR, Jensen E, Polis AB, Johnson-Levonas AO, Brudi P.

Atherosclerosis. 2013 Aug;229(2):415-22. doi: 10.1016/j.atherosclerosis.2013.05.010. Epub 2013 Jun 5.

PMID:
23880197
13.

Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.

Lauring B, Taggart AK, Tata JR, Dunbar R, Caro L, Cheng K, Chin J, Colletti SL, Cote J, Khalilieh S, Liu J, Luo WL, Maclean AA, Peterson LB, Polis AB, Sirah W, Wu TJ, Liu X, Jin L, Wu K, Boatman PD, Semple G, Behan DP, Connolly DT, Lai E, Wagner JA, Wright SD, Cuffie C, Mitchel YB, Rader DJ, Paolini JF, Waters MG, Plump A.

Sci Transl Med. 2012 Aug 22;4(148):148ra115. doi: 10.1126/scitranslmed.3003877.

14.

Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.

Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, Tershakovec AM.

Am J Cardiol. 2010 Feb 15;105(4):487-94. doi: 10.1016/j.amjcard.2009.10.001. Epub 2009 Nov 13.

PMID:
20152243
15.

Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia.

Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis AB, Tipping D, Tomassini JE, Tershakovec AM.

Diabetes Care. 2010 May;33(5):1021-4. doi: 10.2337/dc09-1762. Epub 2010 Feb 11.

16.
17.

The value of a wound score for diabetic foot infections in predicting treatment outcome: a prospective analysis from the SIDESTEP trial.

Lipsky BA, Polis AB, Lantz KC, Norquist JM, Abramson MA.

Wound Repair Regen. 2009 Sep-Oct;17(5):671-7. doi: 10.1111/j.1524-475X.2009.00521.x. Epub 2009 Aug 11.

PMID:
19671126
18.

Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).

Robinson JG, Ballantyne CM, Grundy SM, Hsueh WA, Parving HH, Rosen JB, Adewale AJ, Polis AB, Tomassini JE, Tershakovec AM.

Am J Cardiol. 2009 Jun 15;103(12):1694-702. doi: 10.1016/j.amjcard.2009.05.003.

PMID:
19539078
19.

Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.

Tomassini JE, Mazzone T, Goldberg RB, Guyton JR, Weinstock RS, Polis A, Jensen E, Tershakovec AM.

Diabetes Obes Metab. 2009 Sep;11(9):855-64. doi: 10.1111/j.1463-1326.2009.01061.x. Epub 2009 Jun 5.

PMID:
19508464
20.

Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.

Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM.

J Am Coll Cardiol. 2008 Apr 22;51(16):1564-72. doi: 10.1016/j.jacc.2008.03.003.

21.

Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses.

Abate N, Catapano AL, Ballantyne CM, Davidson MH, Polis A, Smugar SS, Tershakovec AM.

J Clin Lipidol. 2008 Apr;2(2):91-105. doi: 10.1016/j.jacl.2008.02.002. Epub 2008 Feb 15.

PMID:
21291725
22.

Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes.

Weinstock RS, Goldberg RB, Guyton JR, Mazzone T, Polis A, Tomassini JE, Lin J, Shah A, Tershakovec AM.

J Clin Lipidol. 2008 Feb;2(1):25-35. doi: 10.1016/j.jacl.2008.01.001. Epub 2008 Jan 11.

PMID:
21291712
23.

Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes.

Guyton JR, Goldberg RB, Mazzone T, Weinstock RS, Polis A, Rosenberg E, Tershakovec AM.

J Clin Lipidol. 2008 Feb;2(1):19-24. doi: 10.1016/j.jacl.2007.12.004. Epub 2008 Jan 6.

PMID:
21291711
24.

Maternal syphilis and intimate partner violence in Bolivia: a gender-based analysis of implications for partner notification and universal screening.

Díaz-Olavarrieta C, García SG, Feldman BS, Polis AM, Revollo R, Tinajeros F, Grossman D.

Sex Transm Dis. 2007 Jul;34(7 Suppl):S42-6.

PMID:
17592389
25.

Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial.

Lipsky BA, Sheehan P, Armstrong DG, Tice AD, Polis AB, Abramson MA.

Int Wound J. 2007 Mar;4(1):30-8.

PMID:
17425547
26.

Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.

Baraf HS, Fuentealba C, Greenwald M, Brzezicki J, O'Brien K, Soffer B, Polis A, Bird S, Kaur A, Curtis SP; EDGE Study Group.

J Rheumatol. 2007 Feb;34(2):408-20.

PMID:
17304660
27.

Does dermal thermometry predict clinical outcome in diabetic foot infection? Analysis of data from the SIDESTEP* trial.

Armstrong DG, Lipsky BA, Polis AB, Abramson MA.

Int Wound J. 2006 Dec;3(4):302-7.

PMID:
17199766
28.

Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.

Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, Tomassini JE, Tershakovec AM.

Mayo Clin Proc. 2006 Dec;81(12):1579-88. Erratum in: Mayo Clin Proc. 2007 Mar;82(3):387.

PMID:
17165637
29.

Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.

Smugar SS, Schnitzer TJ, Weaver AL, Rubin BR, Polis AB, Tershakovec AM.

Curr Med Res Opin. 2006 Jul;22(7):1353-67.

PMID:
16834834
30.

Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.

Weaver AL, Messner RP, Storms WW, Polis AB, Najarian DK, Petruschke RA, Geba GP, Tershakovec AM.

J Clin Rheumatol. 2006 Feb;12(1):17-25.

PMID:
16484875
31.

Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.

DiNubile MJ, Chow JW, Satishchandran V, Polis A, Motyl MR, Abramson MA, Teppler H.

Antimicrob Agents Chemother. 2005 Aug;49(8):3217-21.

32.

Report of specific cardiovascular outcomes of the ADVANTAGE trial.

Braunstein N, Polis A.

Ann Intern Med. 2005 Jul 19;143(2):158-9. Epub 2005 Jun 20. No abstract available.

PMID:
15968005
33.

Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.

Schnitzer TJ, Weaver AL, Polis AB, Petruschke RA, Geba GP; VACT-1 and VACT-2 (Protocols 106 and 150) Study Groups.

J Rheumatol. 2005 Jun;32(6):1093-105.

PMID:
15940774
34.

The time to onset and overall analgesic efficacy of rofecoxib 50 mg: a meta-analysis of 13 randomized clinical trials.

Desjardins PJ, Mehlisch DR, Chang DJ, Krupa D, Polis AB, Petruschke RA, Malmstrom K, Geba GP.

Clin J Pain. 2005 May-Jun;21(3):241-50.

PMID:
15818076
35.

Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials.

Battisti WP, Katz NP, Weaver AL, Matsumoto AK, Kivitz AJ, Polis AB, Geba GP.

J Pain. 2004 Nov;5(9):511-20.

PMID:
15556830
36.

Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets.

Kolodny A, Polis A, Battisti WP, Johnson-Pratt L, Skobieranda F; Rizatriptan Protocol 052 Study Group.

Cephalalgia. 2004 Jul;24(7):540-6.

PMID:
15196296
37.

Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial.

Kivitz AJ, Greenwald MW, Cohen SB, Polis AB, Najarian DK, Dixon ME, Moidel RA, Green JA, Baraf HS, Petruschke RA, Matsumoto AK, Geba GP; Protocol 085 Study Investigators.

J Am Geriatr Soc. 2004 May;52(5):666-74.

PMID:
15086644
38.

Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.

Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, Dixon ME, Polis AB, Mollen AJ, Geba GP; ADVANTAGE Study Group.

Ann Intern Med. 2003 Oct 7;139(7):539-46.

PMID:
14530224
39.

Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.

Sall KN, Greff LJ, Johnson-Pratt LR, DeLucca PT, Polis AB, Kolodny AH, Fletcher CA, Cassel DA, Boyle DR, Skobieranda F.

Ophthalmology. 2003 Mar;110(3):615-24.

PMID:
12623832
40.

Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone.

Baumgartner RA, Martinez G, Edelman JM, Rodriguez Gomez GG, Bernstein M, Bird S, Angner R, Polis A, Dass SB, Lu S, Reiss TF; Montelukast Asthma Study Group.

Eur Respir J. 2003 Jan;21(1):123-8.

41.

Tolerability and efficacy of dorzolamide versus acetazolamide added to timolol.

Stewart WC, Halper LK, Johnson-Pratt L, Polis A, Hartenbaum D.

J Ocul Pharmacol Ther. 2002 Jun;18(3):211-20.

PMID:
12099542
42.
43.

Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.

Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ; Vioxx, Acetaminophen, Celecoxib Trial (VACT) Group.

JAMA. 2002 Jan 2;287(1):64-71. Erratum in: JAMA 2002 Feb 27;287(8):989.

PMID:
11754710
44.

Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups.

Block GA, Goldstein J, Polis A, Reines SA, Smith ME.

Headache. 1998 Nov-Dec;38(10):764-71.

PMID:
11284464
45.
46.

Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group.

Adamsons IA, Polis A, Ostrov CS, Boyle JE.

J Glaucoma. 1998 Dec;7(6):395-401.

PMID:
9871861
47.

A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group.

Kramer MS, Matzura-Wolfe D, Polis A, Getson A, Amaraneni PG, Solbach MP, McHugh W, Feighner J, Silberstein S, Reines SA.

Neurology. 1998 Sep;51(3):773-81.

PMID:
9748025
48.
49.
50.

Improvement in migraine-specific quality of life in a clinical trial of rizatriptan.

Santanello NC, Polis AB, Hartmaier SL, Kramer MS, Block GA, Silberstein SD.

Cephalalgia. 1997 Dec;17(8):867-72; discussion 800.

PMID:
9453276

Supplemental Content

Support Center